<?xml version="1.0" encoding="UTF-8"?>
<protein>
  <version>3.5</version>
  <creation_date>2013-01-15 18:49:29 -0700</creation_date>
  <update_date>2013-05-27 11:15:25 -0600</update_date>
  <accession>HMDBP00248</accession>
  <secondary_accessions>
    <accession>5480</accession>
    <accession>HMDBP03633</accession>
  </secondary_accessions>
  <protein_type>Enzyme</protein_type>
  <synonyms>
    <synonym>(S)-3-amino-2-methylpropionate transaminase</synonym>
    <synonym>GABA aminotransferase</synonym>
    <synonym>GABA transaminase</synonym>
    <synonym>GABA-AT</synonym>
    <synonym>GABA-T</synonym>
    <synonym>Gamma-amino-N-butyrate transaminase</synonym>
    <synonym>L-AIBAT</synonym>
  </synonyms>
  <gene_name>ABAT</gene_name>
  <general_function>Involved in 4-aminobutyrate transaminase activity</general_function>
  <specific_function>Catalyzes the conversion of gamma-aminobutyrate and L-beta-aminoisobutyrate to succinate semialdehyde and methylmalonate semialdehyde, respectively. Can also convert delta-aminovalerate and beta-alanine.
</specific_function>
  <pathways>
    <pathway>
      <name>Alanine, aspartate and glutamate metabolism</name>
      <smpdb_id/>
      <kegg_map_id>map00250</kegg_map_id>
    </pathway>
    <pathway>
      <name>Valine, leucine and isoleucine degradation</name>
      <smpdb_id/>
      <kegg_map_id>map00280</kegg_map_id>
    </pathway>
    <pathway>
      <name>beta-Alanine metabolism</name>
      <smpdb_id/>
      <kegg_map_id>map00410</kegg_map_id>
    </pathway>
    <pathway>
      <name>Propanoate metabolism</name>
      <smpdb_id/>
      <kegg_map_id>map00640</kegg_map_id>
    </pathway>
    <pathway>
      <name>Butanoate metabolism</name>
      <smpdb_id/>
      <kegg_map_id>map00650</kegg_map_id>
    </pathway>
    <pathway>
      <name>GABAergic synapse</name>
      <smpdb_id/>
      <kegg_map_id>map04727</kegg_map_id>
    </pathway>
  </pathways>
  <metabolite_associations>
    <metabolite>
      <accession>HMDB01491</accession>
      <name>Pyridoxal 5'-phosphate</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00056</accession>
      <name>Beta-Alanine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00112</accession>
      <name>Gamma-Aminobutyric acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00148</accession>
      <name>L-Glutamic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00208</accession>
      <name>Oxoglutaric acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01259</accession>
      <name>Succinic acid semialdehyde</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01919</accession>
      <name>Famotidine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB02166</accession>
      <name>(S)-b-aminoisobutyric acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB02217</accession>
      <name>(S)-Methylmalonic acid semialdehyde</name>
    </metabolite>
    <metabolite>
      <accession>HMDB06284</accession>
      <name>L-2,4-diaminobutyric acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00243</accession>
      <name>Pyruvic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB06805</accession>
      <name>Beta-Alanyl-CoA</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01172</accession>
      <name>2-Methyl-3-oxopropanoic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00691</accession>
      <name>Malonic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB11111</accession>
      <name>Malonic semialdehyde</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00161</accession>
      <name>L-Alanine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB13897</accession>
      <name>4-ene-Valproic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14918</accession>
      <name>Phenelzine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15212</accession>
      <name>Vigabatrin</name>
    </metabolite>
  </metabolite_associations>
  <go_classifications>
    <go_class>
      <category>function</category>
      <description>binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>cofactor binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>pyridoxal phosphate binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>catalytic activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>transferase activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>transferase activity, transferring nitrogenous groups</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>transaminase activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>4-aminobutyrate transaminase activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>metabolic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>cellular metabolic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>cellular amino acid and derivative metabolic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>cellular amino acid derivative metabolic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>gamma-aminobutyric acid metabolic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>Cellular component</category>
      <description>4-aminobutyrate transaminase complex</description>
      <go_id>GO:0032144</go_id>
    </go_class>
    <go_class>
      <category>Cellular component</category>
      <description>mitochondrial matrix</description>
      <go_id>GO:0005759</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>(S)-3-amino-2-methylpropionate transaminase activity</description>
      <go_id>GO:0047298</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>4-aminobutyrate transaminase activity</description>
      <go_id>GO:0003867</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>pyridoxal phosphate binding</description>
      <go_id>GO:0030170</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>succinate-semialdehyde dehydrogenase binding</description>
      <go_id>GO:0032145</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>behavioral response to cocaine</description>
      <go_id>GO:0048148</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>copulation</description>
      <go_id>GO:0007620</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>gamma-aminobutyric acid catabolic process</description>
      <go_id>GO:0009450</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>locomotory behavior</description>
      <go_id>GO:0007626</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>negative regulation of blood pressure</description>
      <go_id>GO:0045776</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>neurotransmitter catabolic process</description>
      <go_id>GO:0042135</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>neurotransmitter secretion</description>
      <go_id>GO:0007269</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>response to drug</description>
      <go_id>GO:0042493</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>response to ethanol</description>
      <go_id>GO:0045471</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>response to hypoxia</description>
      <go_id>GO:0001666</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>response to iron ion</description>
      <go_id>GO:0010039</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>response to nicotine</description>
      <go_id>GO:0035094</go_id>
    </go_class>
  </go_classifications>
  <subcellular_locations>
    <subcellular_location>Mitochondrion matrix</subcellular_location>
  </subcellular_locations>
  <gene_properties>
    <chromosome_location>16</chromosome_location>
    <locus>16p13.2</locus>
    <gene_sequence>&gt;1503 bp
ATGGCCTCCATGTTGCTCGCCCAGCGCCTGGCCTGCAGCTTCCAGCACAGCTACCGCCTG
CTGGTGCCTGGATCCAGACACATTAGTCAAGCTGCAGCCAAAGTCGACGTTGAATTTGAT
TATGATGGGCCTCTGATGAAGACGGAAGTCCCAGGGCCTAGATCTCAGGAGTTAATGAAA
CAGCTGAATATAATTCAGAATGCAGAGGCTGTGCATTTTTTCTGCAATTACGAAGAGAGC
CGAGGCAATTACCTGGTTGATGTGGACGGCAACCGAATGCTGGATCTTTATTCCCAGATC
TCCTCTGTTCCCATAGGTTACAGCCACCCCGCCCTGCTGAAACTCATCCAACAGCCTCAA
AATGCGAGCATGTTTGTCAACAGACCCGCCCTCGGAATCCTGCCTCCGGAGAACTTTGTG
GAGAAGCTCCGGCAGTCCTTGCTCTCGGTGGCTCCCAAAGGGATGTCCCAGCTCATCACC
ATGGCCTGCGGCTCCTGCTCCAATGAAAACGCCTTAAAGACCATCTTCATGTGGTACCGG
AGCAAGGAAAGAGGGCAGAGGGGCTTCTCCCAGGAGGAGCTGGAGACGTGCATGATTAAC
CAGGCCCCTGGCTGCCCCGACTACAGCATCCTCTCCTTCATGGGCGCGTTCCATGGGAGG
ACCATGGGTTGCTTAGCGACCACGCACTCTAAAGCCATTCACAAGATCGACATCCCTTCC
TTTGACTGGCCCATCGCACCGTTCCCACGGCTGAAATACCCTCTGGAAGAGTTTGTGAAA
GAGAACCAACAGGAGGAGGCCCGCTGTCTGGAAGAGGTGGAGGATCTGATTGTGAAATAT
CGGAAAAAGAAGAAGACGGTGGCCGGGATCATCGTGGAGCCCATCCAGTCCGAGGGTGGA
GACAACCACGCATCCGATGACTTCTTTCGGAAGCTGAGAGACATCGCCAGGAAGCATGGC
TGCGCCTTCTTGGTGGACGAGGTACAGACCGGAGGAGGCTGCACGGGCAAGTTCTGGGCC
CATGAGCACTGGGGCCTGGATGACCCAGCAGACGTGATGACCTTCAGCAAGAAGATGATG
ACTGGGGGCTTCTTCCACAAGGAGGAGTTCAGGCCTAATGCTCCCTACCGGATCTTCAAC
ACCTGGCTGGGGGACCCGTCCAAGAACCTGTTGCTGGCTGAGGTCATCAACATCATCAAG
CGGGAGGACCTGCTAAATAATGCAGCCCATGCCGGGAAGGCCCTGCTCACAGGACTGCTG
GACCTCCAGGCCCGGTACCCCCAGTTCATCAGCAGGGTGAGAGGACGAGGCACCTTTTGC
TCCTTCGATACTCCCGATGATTCCATACGGAATAAGCTCATTTTAATTGCCAGAAACAAA
GGTGTGGTGTTGGGTGGCTGTGGTGACAAATCCATTCGTTTCCGTCCCACGCTGGTCTTC
AGGGATCACCACGCTCACCTGTTCCTCAATATTTTCAGTGACATCTTAGCAGACTTCAAG
TAA</gene_sequence>
  </gene_properties>
  <protein_properties>
    <residue_number>500</residue_number>
    <molecular_weight>56438.405</molecular_weight>
    <theoretical_pi>7.961</theoretical_pi>
    <pfams>
      <pfam>
        <name>Aminotran_3</name>
        <pfam_id>PF00202</pfam_id>
      </pfam>
    </pfams>
    <transmembrane_regions>
    </transmembrane_regions>
    <signal_regions>
    </signal_regions>
    <protein_sequence>&gt;4-aminobutyrate aminotransferase, mitochondrial
MASMLLAQRLACSFQHSYRLLVPGSRHISQAAAKVDVEFDYDGPLMKTEVPGPRSQELMK
QLNIIQNAEAVHFFCNYEESRGNYLVDVDGNRMLDLYSQISSVPIGYSHPALLKLIQQPQ
NASMFVNRPALGILPPENFVEKLRQSLLSVAPKGMSQLITMACGSCSNENALKTIFMWYR
SKERGQRGFSQEELETCMINQAPGCPDYSILSFMGAFHGRTMGCLATTHSKAIHKIDIPS
FDWPIAPFPRLKYPLEEFVKENQQEEARCLEEVEDLIVKYRKKKKTVAGIIVEPIQSEGG
DNHASDDFFRKLRDIARKHGCAFLVDEVQTGGGCTGKFWAHEHWGLDDPADVMTFSKKMM
TGGFFHKEEFRPNAPYRIFNTWLGDPSKNLLLAEVINIIKREDLLNNAAHAGKALLTGLL
DLQARYPQFISRVRGRGTFCSFDTPDDSIRNKLILIARNKGVVLGGCGDKSIRFRPTLVF
RDHHAHLFLNIFSDILADFK</protein_sequence>
  </protein_properties>
  <genbank_protein_id>158254434</genbank_protein_id>
  <uniprot_id>P80404</uniprot_id>
  <uniprot_name>GABT_HUMAN</uniprot_name>
  <pdb_ids>
  </pdb_ids>
  <genbank_gene_id>AK290501</genbank_gene_id>
  <genecard_id>ABAT</genecard_id>
  <geneatlas_id>ABAT</geneatlas_id>
  <hgnc_id>HGNC:23</hgnc_id>
  <general_references>
    <reference>
      <reference_text>Osei YD, Churchich JE: Screening and sequence determination of a cDNA encoding the human brain 4-aminobutyrate aminotransferase. Gene. 1995 Apr 3;155(2):185-7.</reference_text>
      <pubmed_id>7721088</pubmed_id>
    </reference>
    <reference>
      <reference_text>Ota T, Suzuki Y, Nishikawa T, Otsuki T, Sugiyama T, Irie R, Wakamatsu A, Hayashi K, Sato H, Nagai K, Kimura K, Makita H, Sekine M, Obayashi M, Nishi T, Shibahara T, Tanaka T, Ishii S, Yamamoto J, Saito K, Kawai Y, Isono Y, Nakamura Y, Nagahari K, Murakami K, Yasuda T, Iwayanagi T, Wagatsuma M, Shiratori A, Sudo H, Hosoiri T, Kaku Y, Kodaira H, Kondo H, Sugawara M, Takahashi M, Kanda K, Yokoi T, Furuya T, Kikkawa E, Omura Y, Abe K, Kamihara K, Katsuta N, Sato K, Tanikawa M, Yamazaki M, Ninomiya K, Ishibashi T, Yamashita H, Murakawa K, Fujimori K, Tanai H, Kimata M, Watanabe M, Hiraoka S, Chiba Y, Ishida S, Ono Y, Takiguchi S, Watanabe S, Yosida M, Hotuta T, Kusano J, Kanehori K, Takahashi-Fujii A, Hara H, Tanase TO, Nomura Y, Togiya S, Komai F, Hara R, Takeuchi K, Arita M, Imose N, Musashino K, Yuuki H, Oshima A, Sasaki N, Aotsuka S, Yoshikawa Y, Matsunawa H, Ichihara T, Shiohata N, Sano S, Moriya S, Momiyama H, Satoh N, Takami S, Terashima Y, Suzuki O, Nakagawa S, Senoh A, Mizoguchi H, Goto Y, Shimizu F, Wakebe H, Hishigaki H, Watanabe T, Sugiyama A, Takemoto M, Kawakami B, Yamazaki M, Watanabe K, Kumagai A, Itakura S, Fukuzumi Y, Fujimori Y, Komiyama M, Tashiro H, Tanigami A, Fujiwara T, Ono T, Yamada K, Fujii Y, Ozaki K, Hirao M, Ohmori Y, Kawabata A, Hikiji T, Kobatake N, Inagaki H, Ikema Y, Okamoto S, Okitani R, Kawakami T, Noguchi S, Itoh T, Shigeta K, Senba T, Matsumura K, Nakajima Y, Mizuno T, Morinaga M, Sasaki M, Togashi T, Oyama M, Hata H, Watanabe M, Komatsu T, Mizushima-Sugano J, Satoh T, Shirai Y, Takahashi Y, Nakagawa K, Okumura K, Nagase T, Nomura N, Kikuchi H, Masuho Y, Yamashita R, Nakai K, Yada T, Nakamura Y, Ohara O, Isogai T, Sugano S: Complete sequencing and characterization of 21,243 full-length human cDNAs. Nat Genet. 2004 Jan;36(1):40-5. Epub 2003 Dec 21.</reference_text>
      <pubmed_id>14702039</pubmed_id>
    </reference>
    <reference>
      <reference_text>Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G, Klein SL, Old S, Rasooly R, Good P, Guyer M, Peck AM, Derge JG, Lipman D, Collins FS, Jang W, Sherry S, Feolo M, Misquitta L, Lee E, Rotmistrovsky K, Greenhut SF, Schaefer CF, Buetow K, Bonner TI, Haussler D, Kent J, Kiekhaus M, Furey T, Brent M, Prange C, Schreiber K, Shapiro N, Bhat NK, Hopkins RF, Hsie F, Driscoll T, Soares MB, Casavant TL, Scheetz TE, Brown-stein MJ, Usdin TB, Toshiyuki S, Carninci P, Piao Y, Dudekula DB, Ko MS, Kawakami K, Suzuki Y, Sugano S, Gruber CE, Smith MR, Simmons B, Moore T, Waterman R, Johnson SL, Ruan Y, Wei CL, Mathavan S, Gunaratne PH, Wu J, Garcia AM, Hulyk SW, Fuh E, Yuan Y, Sneed A, Kowis C, Hodgson A, Muzny DM, McPherson J, Gibbs RA, Fahey J, Helton E, Ketteman M, Madan A, Rodrigues S, Sanchez A, Whiting M, Madari A, Young AC, Wetherby KD, Granite SJ, Kwong PN, Brinkley CP, Pearson RL, Bouffard GG, Blakesly RW, Green ED, Dickson MC, Rodriguez AC, Grimwood J, Schmutz J, Myers RM, Butterfield YS, Griffith M, Griffith OL, Krzywinski MI, Liao N, Morin R, Palmquist D, Petrescu AS, Skalska U, Smailus DE, Stott JM, Schnerch A, Schein JE, Jones SJ, Holt RA, Baross A, Marra MA, Clifton S, Makowski KA, Bosak S, Malek J: The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). Genome Res. 2004 Oct;14(10B):2121-7.</reference_text>
      <pubmed_id>15489334</pubmed_id>
    </reference>
    <reference>
      <reference_text>De Biase D, Barra D, Simmaco M, John RA, Bossa F: Primary structure and tissue distribution of human 4-aminobutyrate aminotransferase. Eur J Biochem. 1995 Jan 15;227(1-2):476-80.</reference_text>
      <pubmed_id>7851425</pubmed_id>
    </reference>
    <reference>
      <reference_text>Medina-Kauwe LK, Tobin AJ, De Meirleir L, Jaeken J, Jakobs C, Nyhan WL, Gibson KM: 4-Aminobutyrate aminotransferase (GABA-transaminase) deficiency.  J Inherit Metab Dis. 1999 Jun;22(4):414-27.</reference_text>
      <pubmed_id>10407778</pubmed_id>
    </reference>
  </general_references>
  <metabolite_references>
    <metabolite_reference>
      <metabolite>
        <name>L-Glutamic acid</name>
        <accession>HMDB00148</accession>
      </metabolite>
      <reference>
        <reference_text>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there?  Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</reference_text>
        <pubmed_id>17139284</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>L-Glutamic acid</name>
        <accession>HMDB00148</accession>
      </metabolite>
      <reference>
        <reference_text>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets.  Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</reference_text>
        <pubmed_id>17016423</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>L-Glutamic acid</name>
        <accession>HMDB00148</accession>
      </metabolite>
      <reference>
        <reference_text>Imai H, Okuno T, Wu JY, Lee TJ: GABAergic innervation in cerebral blood vessels: an immunohistochemical demonstration of L-glutamic acid decarboxylase and GABA transaminase. J Cereb Blood Flow Metab. 1991 Jan;11(1):129-34.</reference_text>
        <pubmed_id>1983997</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>L-Glutamic acid</name>
        <accession>HMDB00148</accession>
      </metabolite>
      <reference>
        <reference_text>Happola O, Paivarinta H, Soinila S, Wu JY, Panula P: Localization of L-glutamate decarboxylase and GABA transaminase immunoreactivity in the sympathetic ganglia of the rat. Neuroscience. 1987 Apr;21(1):271-81.</reference_text>
        <pubmed_id>3299141</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>L-Glutamic acid</name>
        <accession>HMDB00148</accession>
      </metabolite>
      <reference>
        <reference_text>Far SR, Millimoria FR: Levels of glutamic acid decarboxylase (GAD), gamma amino butyric acid transaminase (GABA-T), glutamic acid dehydrogenase (GLDH) and proteins in cerebrospinal fluid of certain neurological disorders. Indian J Med Sci. 1996 Apr;50(4):99-102.</reference_text>
        <pubmed_id>8979623</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pyruvic acid</name>
        <accession>HMDB00243</accession>
      </metabolite>
      <reference>
        <reference_text>Andersen G, Andersen B, Dobritzsch D, Schnackerz KD, Piskur J: A gene duplication led to specialized gamma-aminobutyrate and beta-alanine aminotransferase in yeast. FEBS J. 2007 Apr;274(7):1804-17. Epub 2007 Mar 12.</reference_text>
        <pubmed_id>17355287</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pyruvic acid</name>
        <accession>HMDB00243</accession>
      </metabolite>
      <reference>
        <reference_text>Schmidt C, Hofmann U, Kohlmuller D, Murdter T, Zanger UM, Schwab M, Hoffmann GF: Comprehensive analysis of pyrimidine metabolism in 450 children with unspecific neurological symptoms using high-pressure liquid chromatography-electrospray ionization tandem mass spectrometry. J Inherit Metab Dis. 2005;28(6):1109-22.</reference_text>
        <pubmed_id>16435204</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pyruvic acid</name>
        <accession>HMDB00243</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>L-Alanine</name>
        <accession>HMDB00161</accession>
      </metabolite>
      <reference>
        <reference_text>Amadasi A, Bertoldi M, Contestabile R, Bettati S, Cellini B, di Salvo ML, Borri-Voltattorni C, Bossa F, Mozzarelli A: Pyridoxal 5'-phosphate enzymes as targets for therapeutic agents.  Curr Med Chem. 2007;14(12):1291-324.</reference_text>
        <pubmed_id>17504214</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>L-Alanine</name>
        <accession>HMDB00161</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>4-ene-Valproic acid</name>
        <accession>HMDB13897</accession>
      </metabolite>
      <reference>
        <reference_text>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there?  Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</reference_text>
        <pubmed_id>17139284</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>4-ene-Valproic acid</name>
        <accession>HMDB13897</accession>
      </metabolite>
      <reference>
        <reference_text>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets.  Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</reference_text>
        <pubmed_id>17016423</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>4-ene-Valproic acid</name>
        <accession>HMDB13897</accession>
      </metabolite>
      <reference>
        <reference_text>Loscher W: Anticonvulsant and biochemical effects of inhibitors of GABA aminotransferase and valproic acid during subchronic treatment in mice. Biochem Pharmacol. 1982 Mar 1;31(5):837-42.</reference_text>
        <pubmed_id>6805473</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>4-ene-Valproic acid</name>
        <accession>HMDB13897</accession>
      </metabolite>
      <reference>
        <reference_text>Ha JH, Lee DU, Lee JT, Kim JS, Yong CS, Kim JA, Ha JS, Huh K: 4-Hydroxybenzaldehyde from Gastrodia elata B1. is active in the antioxidation and GABAergic neuromodulation of the rat brain. J Ethnopharmacol. 2000 Nov;73(1-2):329-33.</reference_text>
        <pubmed_id>11025174</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>4-ene-Valproic acid</name>
        <accession>HMDB13897</accession>
      </metabolite>
      <reference>
        <reference_text>Semba J, Kuroda Y, Takahashi R: Potential antidepressant properties of subchronic GABA transaminase inhibitors in the forced swimming test in mice. Neuropsychobiology. 1989;21(3):152-6.</reference_text>
        <pubmed_id>2559361</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>4-ene-Valproic acid</name>
        <accession>HMDB13897</accession>
      </metabolite>
      <reference>
        <reference_text>Rosenberg G: The mechanisms of action of valproate in neuropsychiatric disorders: can we see the forest for the trees? Cell Mol Life Sci. 2007 Aug;64(16):2090-103.</reference_text>
        <pubmed_id>17514356</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Phenelzine</name>
        <accession>HMDB14918</accession>
      </metabolite>
      <reference>
        <reference_text>MacKenzie EM, Grant SL, Baker GB, Wood PL: Phenelzine causes an increase in brain ornithine that is prevented by prior monoamine oxidase inhibition. Neurochem Res. 2008 Mar;33(3):430-6. Epub 2007 Aug 31.</reference_text>
        <pubmed_id>17768678</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Phenelzine</name>
        <accession>HMDB14918</accession>
      </metabolite>
      <reference>
        <reference_text>Tanay VA, Parent MB, Wong JT, Paslawski T, Martin IL, Baker GB: Effects of the antidepressant/antipanic drug phenelzine on alanine and alanine transaminase in rat brain. Cell Mol Neurobiol. 2001 Aug;21(4):325-39.</reference_text>
        <pubmed_id>11775064</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Phenelzine</name>
        <accession>HMDB14918</accession>
      </metabolite>
      <reference>
        <reference_text>McKenna KF, McManus DJ, Baker GB, Coutts RT: Chronic administration of the antidepressant phenelzine and its N-acetyl analogue: effects on GABAergic function. J Neural Transm Suppl. 1994;41:115-22.</reference_text>
        <pubmed_id>7931216</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Phenelzine</name>
        <accession>HMDB14918</accession>
      </metabolite>
      <reference>
        <reference_text>McManus DJ, Baker GB, Martin IL, Greenshaw AJ, McKenna KF: Effects of the antidepressant/antipanic drug phenelzine on GABA concentrations and GABA-transaminase activity in rat brain. Biochem Pharmacol. 1992 Jun 9;43(11):2486-9.</reference_text>
        <pubmed_id>1610412</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Phenelzine</name>
        <accession>HMDB14918</accession>
      </metabolite>
      <reference>
        <reference_text>Todd KG, Baker GB: GABA-elevating effects of the antidepressant/antipanic drug phenelzine in brain: effects of pretreatment with tranylcypromine, (-)-deprenyl and clorgyline. J Affect Disord. 1995 Dec 13;35(3):125-9.</reference_text>
        <pubmed_id>8749840</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Phenelzine</name>
        <accession>HMDB14918</accession>
      </metabolite>
      <reference>
        <reference_text>Todd KG, Baker GB: Neurochemical effects of the monoamine oxidase inhibitor phenelzine on brain GABA and alanine: A comparison with vigabatrin. J Pharm Pharm Sci. 2008 May 16;11(2):14s-21s.</reference_text>
        <pubmed_id>19203467</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Phenelzine</name>
        <accession>HMDB14918</accession>
      </metabolite>
      <reference>
        <reference_text>McKenna KF, Baker GB, Coutts RT: N2-acetylphenelzine: effects on rat brain GABA, alanine and biogenic amines.  Naunyn Schmiedebergs Arch Pharmacol. 1991 May;343(5):478-82.</reference_text>
        <pubmed_id>1881457</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Vigabatrin</name>
        <accession>HMDB15212</accession>
      </metabolite>
      <reference>
        <reference_text>Weber OM, Verhagen A, Duc CO, Meier D, Leenders KL, Boesiger P: Effects of vigabatrin intake on brain GABA activity as monitored by spectrally edited magnetic resonance spectroscopy and positron emission tomography. Magn Reson Imaging. 1999 Apr;17(3):417-25.</reference_text>
        <pubmed_id>10195585</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Vigabatrin</name>
        <accession>HMDB15212</accession>
      </metabolite>
      <reference>
        <reference_text>Valdizan EM, Garcia AP, Armijo JA: Effects of increasing doses of vigabatrin on platelet gamma-aminobutyric acid-transaminase and brain gamma-aminobutyric acid in rats. Eur J Pharmacol. 1999 Mar 19;369(2):169-73.</reference_text>
        <pubmed_id>10206175</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Vigabatrin</name>
        <accession>HMDB15212</accession>
      </metabolite>
      <reference>
        <reference_text>Arndt CF, Derambure P, Defoort-Dhellemmes S, Hache JC: Outer retinal dysfunction in patients treated with vigabatrin.  Neurology. 1999 Apr 12;52(6):1201-5.</reference_text>
        <pubmed_id>10214744</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Vigabatrin</name>
        <accession>HMDB15212</accession>
      </metabolite>
      <reference>
        <reference_text>Molina PE, Ahmed N, Ajmal M, Dewey S, Volkow N, Fowler J, Abumrad N: Co-administration of gamma-vinyl GABA and cocaine: preclinical assessment of safety. Life Sci. 1999;65(11):1175-82.</reference_text>
        <pubmed_id>10503933</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Vigabatrin</name>
        <accession>HMDB15212</accession>
      </metabolite>
      <reference>
        <reference_text>French JA: Vigabatrin.  Epilepsia. 1999;40 Suppl 5:S11-6.</reference_text>
        <pubmed_id>10530689</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Vigabatrin</name>
        <accession>HMDB15212</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
  </metabolite_references>
</protein>
